Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.

Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Bilous RW.

J Hum Hypertens. 2004 Oct;18(10):733-8.

PMID:
15116142
3.

[Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective].

Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, de Alvaro F; Grupo de Estudio Colaborativo IDNT.

Nefrologia. 2004;24(3):231-8. Spanish.

4.

[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].

Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Ritz E.

Dtsch Med Wochenschr. 2004 Jan 2;129(1-2):13-8. German.

PMID:
14703575
5.

Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies.

Palmer AJ, Tucker DM, Valentine WJ, Roze S, Gabriel S, Cordonnier DJ.

Nephrol Dial Transplant. 2005 Jun;20(6):1103-9. Epub 2005 Apr 26. Review.

PMID:
15855214
6.

Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.

Palmer AJ, Valentine WJ, Ray JA.

Int J Clin Pract. 2007 Oct;61(10):1626-33. Review.

PMID:
17877649
7.

[Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].

Palmer AJ, Roze S, Rodby RA, Valentine WJ, Ritz E, Lehnert H.

Dtsch Med Wochenschr. 2006 Aug 4;131(31-32):1721-6. German.

PMID:
16868875
8.

The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.

Rodby RA, Chiou CF, Borenstein J, Smitten A, Sengupta N, Palmer AJ, Roze S, Annemans L, Simon TA, Chen RS, Lewis EJ; Collaborative Study Group.

Clin Ther. 2003 Jul;25(7):2102-19.

PMID:
12946554
9.
10.

[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].

Frei A, Palmer AJ, Burnier M, Hess B.

Praxis (Bern 1994). 2006 Mar 15;95(11):401-8. German.

PMID:
16570646
13.

Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.

Coyle D, Rodby R, Soroka S, Levin A, Muirhead N, de Cotret PR, Chen R, Palmer A.

Clin Ther. 2007 Jul;29(7):1508-23.

PMID:
17825702
14.

Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.

Palmer AJ, Annemans L, Roze S, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, De Alvaro F.

Kidney Int Suppl. 2005 Jan;(93):S52-4.

PMID:
15613069
15.

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.

Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, Laville M.

Curr Med Res Opin. 2006 Nov;22(11):2095-100.

PMID:
17076969
16.

Pharmacoeconomic challenges in the management of diabetic nephropathy.

Rodby RA.

J Manag Care Pharm. 2004 Sep;10(5 Suppl A):S6-11.

17.
18.

Economic evaluation of angiotensin receptor blockers in type 2 diabetes, hypertension, and nephropathy.

Ravera M, Re M, Vettoretti S.

J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S44-8. Review.

19.
20.

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.

Ann Intern Med. 2003 Apr 1;138(7):542-9.

PMID:
12667024

Supplemental Content

Support Center